Table 2.
Crude and PCR adjusted days 14 and 28 treatment outcomes of study participants on AS/AQ or AL.
| Efficacy outcome | AS/AQ | AL | ||
|---|---|---|---|---|
| N | % | N | % | |
| Crude day 14 cure rates | 68 | 69 | ||
| ACPR | 61 | 89.7 | 67 | 97.1 |
| ETF | 02 | 02.9 | 0 | 0 |
| LCF | 01 | 01.5 | 0 | 0 |
| LPF | 04 | 06.0 | 02 | 03.0 |
| Crude day 28 cure rates | 61 | 64 | ||
| ACPR | 54 | 88.5 | 62 | 96.9 |
| ETF | 02 | 03.3 | 0 | 0 |
| LCF | 01 | 01.6 | 0 | 0 |
| LPF | 04 | 06.6 | 02 | 03.1 |
| PCR corrected day 28 cure rates | 56 | 62 | ||
| ACPR | 54 | 96.4 | 62 | 100 |
| ETF | 02 | 03.6 | 0 | 0 |
| LCF | 0 | 0 | 0 | 0 |
| LPF | 0 | 0 | 0 | 0 |
Note: Reinfections were excluded from the analysis after profiling pretreatment and recurrent parasites based on the polymorphic Plasmodium falciparum msp 2 antigen. ACPR: adequate clinical parasitological response, ETF: early treatment failure, LCF: late clinical failure, LPF: late parasitological failure, and CI: confidence interval. Early treatment failures were noted in two patients randomized to receive ASAQ coblister. It was unclear if this was due to poor drug absorption or real treatment failures.